scarletred
  • Home
  • Company
  • Products
    Scarletred®Vision
    Scarletred®Telemedicine
  • Services
  • Applications
  • News
  • Contact
Menu
01
Home
02
Company
03
Products
04
Services
05
Applications
06
News
07
Contact
Get in touch
Austria
SCARLETRED Holding GmbH
MQM 3.4, Maria Jacobi Gasse 1,
8th floor, 1030 Vienna, Austria
USA
SCARLETRED Inc.
1 Broadway, 14th floor,
Cambridge, MA 02142, USA
office@scarletred.com
Privacy Policy
Social
Linkedin
Linkedin
Linkedin
Twitter
Instagram
Instagram
Facebook
Facebook
info
Press
Career
FAQ
Regulatory
Imprint

Safety monitoring

Keywords:
#
JAK inhibitors
#
GlobalFemaleLeaders
#
GFL
#
EWMD
#
Arab Health 2022
#
Clinical Trial
#
Discovery Program
No items found.
SCARLETRED used in Janus kinase inhibitor safety testing and monitoring
Article
•
Jun 6, 2022

SCARLETRED skin monitoring helps to make treatments with JAK inhibitors safer

With patient safety in mind, SCARLETRED®Vision can be used as a digital aid to measure and document treatment safety and efficacy of newly developed JAK inhibitors either on site and/or home based clinical trials.
Publication
•
September 27, 2021

The mathematics of erythema: Development of machine learning models for artificial intelligence assisted measurement and severity scoring of radiation induced dermatitis

Read more
Find us
  • SCARLETRED Holding GmbH 
    MQM 3.4, Maria Jacobi Gasse 1, 8th floor, 1030 Vienna, Austria
    ‍
    SCARLETRED Inc.
    1 Broadway, 14th floor,
    Cambridge, MA 02142, USA
About us
  • Company
  • Products
  • Services
  • Applications
  • News
Contact us
  • Press
  • Career
  • FAQ
  • Regulatory
  • Contact
Request a demo
Sign in
© 2021 SCARLETRED Holding GmbH
Home
Contact
Imprint
Terms and Conditions